Condition / Condition conditions

IBS and Anxiety

IBS and anxiety frequently travel together through a shared gut–brain axis. IBS is a disorder of gut–brain interaction defined by recurrent abdominal pain with altered bowel habits, while anxiety encompasses excessive worry with physiological arousal. Epidemiologically, anxiety is far more common in people with IBS than in the general population, and IBS risk is elevated among those with anxiety, suggesting a bidirectional relationship. Mechanistically, chronic stress and hypothalamic–pituitary–adrenal (HPA) axis dysregulation, autonomic imbalance (reduced vagal tone), low-grade mucosal immune activation, and alterations in microbiota and microbial metabolites can sensitize visceral pain pathways and amplify interoceptive threat appraisal—core drivers of both IBS symptoms and anxiety. Serotonin signaling is central: about 95% of serotonin is produced in the gut, where it modulates motility and sensation; peripheral serotonergic changes may influence central mood circuitry via immune, neural, and metabolic routes. Clinically, the overlap has practical implications. Screening IBS patients for anxiety (and vice versa) improves care planning. Psychological therapies tailored to the gut–brain axis—particularly cognitive behavioral therapy (CBT, including gut-directed variants) and gut-directed hypnotherapy—show meaningful, durable improvements in global IBS symptoms, abdominal pain, and anxiety. Exercise, sleep optimization, and mindfulness-based practices support both conditions through autonomic and stress-coping pathways. Pharmacologically, antidepressants can help IBS even in the absence of major depression or anxiety: low-dose tricyclics reduce pain and slow diarrhea, while SSRIs/SNRIs may help global symptoms and comorbid anxiety, sometimes loosening stools (useful for IBS-C, potentially aggravating for IBS-D). Dietary therapy (especially a structured low-FODMAP approach with reintroduction) has strong evidence for IBS symptom control and may secondarily reduce ar

Updated March 1, 2026

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication regimen.

Shared Risk Factors

Chronic stress and HPA-axis dysregulation

Strong Evidence

Persistent psychosocial stress elevates CRF and cortisol, heightening visceral sensitivity and motility changes while reinforcing hypervigilance and worry.

Exacerbates abdominal pain, urgency/constipation via motility/sensitivity changes.
Sustains physiological arousal and worry; lowers stress tolerance.

Female sex and hormonal fluctuations

Moderate Evidence

IBS and anxiety are both more prevalent in women; perimenstrual hormone shifts can modulate visceral pain and affect.

Symptoms often flare around menses; estrogen/progesterone affect motility.
Hormonal transitions can increase anxiety sensitivity.

Early-life adversity (ACEs)

Moderate Evidence

Childhood adversity primes stress circuits and pain amplification, increasing risk for disorders of gut–brain interaction and anxiety.

Greater risk of adult IBS and pain chronicity.
Higher lifetime anxiety risk and symptom severity.

Sleep disturbance/insomnia

Moderate Evidence

Bidirectional links between poor sleep, pain sensitivity, and anxiety; sleep loss amplifies threat processing.

Worsens pain, bowel irregularity, and fatigue.
Heightens anxiety and reduces emotion regulation.

Gut microbiome dysbiosis and antibiotic exposure

Moderate Evidence

Microbial diversity and metabolite shifts are associated with IBS; emerging psychobiotic research links microbiota to stress reactivity and mood.

Associated with IBS symptoms and visceral hypersensitivity.
Alters stress responses and may influence anxiety via vagal and immune pathways.

Autonomic imbalance (low vagal tone)

Emerging Research

Reduced parasympathetic/vagal activity is observed in both conditions, affecting motility, inflammation, and arousal.

Contributes to dysmotility and heightened gut sensation.
Maintains hyperarousal and worry loops.

Serotonin signaling variants and tryptophan metabolism

Emerging Research

Peripheral 5-HT regulates GI motility and pain; polymorphisms and kynurenine pathway shifts may influence central anxiety.

Alters secretion and motility patterns (IBS-D/C).
May modulate anxiety circuits and stress coping.

Low-grade mucosal immune activation/mast cells

Moderate Evidence

Mast cells near enteric nerves correlate with pain in IBS; inflammatory mediators affect mood circuits.

Sensitizes afferents and increases pain.
Cytokines can promote anxious affect and fatigue.

Diet quality (high-FODMAP/ultra-processed patterns)

Moderate Evidence

Fermentable carbohydrates and additives increase luminal distension; diet quality links to mood through metabolic and inflammatory pathways.

Triggers bloating, pain, altered stools in susceptible individuals.
Poor diet quality associates with higher anxiety risk; causality less clear.

Physical inactivity

Moderate Evidence

Regular activity reduces IBS severity and anxiety; sedentariness increases risk for both.

Improves transit, pain tolerance, and QoL.
Reduces anxious arousal and improves sleep.

Comorbidity Data

Prevalence

Meta-analyses estimate anxiety in IBS at roughly 30–40% (versus ~7–10% general population). Individuals with anxiety have 2–3× higher odds of IBS compared with controls.

Mechanistic Link

A bidirectional gut–brain axis integrates central stress circuits, autonomic output, enteroendocrine serotonin signaling, mucosal immune activity, and microbial metabolites. Stress and anxiety amplify top‑down threat appraisal of visceral signals, while peripheral sensitization (mast cells, cytokines, bile acids, 5‑HT) increases bottom‑up nociceptive input to the brain.

Clinical Implications

Routinely screen IBS patients for anxiety and address both domains. Consider sequencing: stabilize severe anxiety (sleep, CBT, SSRIs/SNRIs) to improve IBS self‑management, or start gut-focused therapy (CBT‑GI, hypnotherapy, low‑FODMAP) to reduce symptom-driven anxiety. Match antidepressant class to bowel pattern (TCAs often for IBS‑D; SSRIs may suit IBS‑C). Avoid long‑term benzodiazepines. Multidisciplinary care (GI, behavioral health, dietetics) improves outcomes.

Sources (3)
  1. Zamani M et al. Aliment Pharmacol Ther. 2019;50:132-143. doi:10.1111/apt.15223
  2. Mayer EA et al. J Clin Invest. 2015;125:926-938. doi:10.1172/JCI76304
  3. Cryan JF et al. Physiol Rev. 2019;99:1877-2013. doi:10.1152/physrev.00018.2018

Overlapping Treatments

Cognitive behavioral therapy (including gut-directed CBT)

Strong Evidence
Benefits for IBS

Improves global IBS symptoms, pain, and quality of life; durable effects.

Benefits for Anxiety

Reduces worry, catastrophic thinking, and avoidance; improves coping.

Access and therapist availability can limit uptake; digital/remote programs are alternatives.

Gut-directed hypnotherapy

Moderate Evidence
Benefits for IBS

Reduces pain, bloating, and bowel dysfunction via autonomic modulation and expectancy shifts.

Benefits for Anxiety

Lowers arousal and anxiety, improves interoceptive tolerance.

Requires trained providers; response may take several sessions.

Antidepressants (SSRIs/SNRIs)

Moderate Evidence
Benefits for IBS

May improve global IBS symptoms and comorbid mood/anxiety via central modulation of pain.

Benefits for Anxiety

First-line for many anxiety disorders.

SSRIs can loosen stools (helpful in IBS‑C, problematic in IBS‑D); side effects and activation should be monitored.

Low-dose tricyclic antidepressants (e.g., amitriptyline, nortriptyline)

Strong Evidence
Benefits for IBS

Analgesic effect and anticholinergic slowing benefit pain and diarrhea (IBS‑D).

Benefits for Anxiety

Anxiolytic/sedating properties in some patients.

May worsen constipation (IBS‑C), cause dry mouth, somnolence; cardiac caution at higher doses.

Mindfulness-based stress reduction/meditation

Moderate Evidence
Benefits for IBS

Improves pain acceptance and symptom-related distress.

Benefits for Anxiety

Reduces anxiety and reactivity; enhances emotion regulation.

Requires practice consistency; effects build over weeks.

Exercise (aerobic/resistance)

Moderate Evidence
Benefits for IBS

Improves transit and pain thresholds; reduces global severity.

Benefits for Anxiety

Anxiolytic via HPA-axis and neurotrophic effects; improves sleep.

Start gradually to avoid symptom flares; aim for 150+ minutes/week as tolerated.

Sleep optimization and CBT-I

Moderate Evidence
Benefits for IBS

Better sleep reduces pain sensitivity and GI symptom flares.

Benefits for Anxiety

Directly reduces anxiety severity and next-day arousal.

CBT-I access may be limited; digital programs can help.

Dietary therapy (low-FODMAP with structured reintroduction)

Strong Evidence
Benefits for IBS

Strong evidence for reducing pain, bloating, and stool abnormalities.

Benefits for Anxiety

Improves quality of life; may indirectly reduce anxiety by lowering symptom burden.

Use dietitian guidance; avoid unnecessary long-term restriction to protect microbiome and nutrition.

Probiotics/psychobiotics (strain-specific)

Emerging Research
Benefits for IBS

Some strains reduce bloating and pain; modest global benefits.

Benefits for Anxiety

Emerging evidence for reduced stress/anxiety in select strains.

Strain and dose matter; benefits are modest and not universal.

Yoga and diaphragmatic breathing (vagal toning)

Moderate Evidence
Benefits for IBS

May reduce pain and normalize motility via autonomic balance.

Benefits for Anxiety

Lowers physiological arousal and anxiety; improves HRV.

Choose gentle forms during flares; consistency is key.

Acupuncture

Emerging Research
Benefits for IBS

Some trials show improvement in global IBS symptoms and pain.

Benefits for Anxiety

May reduce anxiety through autonomic and limbic modulation.

Evidence quality mixed; effects may depend on practitioner and protocol.

Medical Perspectives

Western Perspective

Western medicine frames IBS–anxiety comorbidity within the bidirectional gut–brain axis. Central stress circuits and cognitive–affective processes modulate visceral sensitivity, while peripheral gut factors (5‑HT signaling, immune activity, microbiota) influence brain function. Multimodal care—behavioral, dietary, and when appropriate pharmacologic—yields the best outcomes.

Key Insights

  • Anxiety is common in IBS and independently worsens symptom severity and health care use.
  • Treatments targeting central processing (CBT, hypnotherapy, antidepressants) can improve IBS even without major psychiatric diagnoses.
  • Selecting antidepressants by bowel pattern (SSRIs for IBS‑C, TCAs for IBS‑D) can maximize benefit and minimize side effects.
  • Low-FODMAP diet is effective for IBS symptoms; psychological therapies add incremental benefit on anxiety and QoL.

Treatments

  • CBT (including GI‑focused variants) and gut-directed hypnotherapy
  • Low-FODMAP diet with reintroduction; general diet quality improvement
  • Antidepressants (TCAs, SSRIs/SNRIs) matched to bowel pattern
  • Exercise, sleep optimization, mindfulness-based interventions
Evidence: Strong Evidence

Sources

  • Lacy BE et al. Am J Gastroenterol. 2021;116:17-44. doi:10.14309/ajg.0000000000001036
  • Black CJ et al. Gut. 2020;69:1441-1451. doi:10.1136/gutjnl-2019-320041
  • Dionne J et al. Neurogastroenterol Motil. 2018;30:e13154
  • Ford AC et al. Am J Gastroenterol. 2019;114:1886-1900

Eastern Perspective

Eastern traditions view IBS and anxiety as interwoven disturbances of systemic balance. In Traditional Chinese Medicine (TCM), Liver Qi stagnation ‘overacting’ on Spleen/Stomach with attendant Shen disturbance explains stress-reactive bowels and anxious mood; treatment harmonizes Liver–Spleen, regulates Qi, and calms Shen via acupuncture and classic formulas. Ayurveda frames many IBS phenotypes as Vata‑dominant ‘Grahani’ with disturbed Agni (digestion) and rajas/tamas imbalance affecting mind; therapy pacifies Vata, stabilizes digestion, and soothes the nervous system through diet, herbs, yoga, and pranayama.

Key Insights

  • Pattern differentiation (e.g., Liver–Spleen disharmony; Vata aggravation) guides individualized treatment of both gut and mind.
  • Acupuncture and mind–body practices modulate autonomic tone, offering a physiological bridge to Western gut–brain models.
  • Selected herbal formulas (e.g., Xiao Yao San; Tong Xie Yao Fang) and adaptogens (e.g., ashwagandha) show emerging evidence for mood and IBS symptoms.

Treatments

  • Acupuncture protocols often using ST36, ST25, LR3, SP6, PC6, and CV12 to regulate gut and calm Shen
  • TCM herbal formulas such as Xiao Yao San (Liver–Spleen disharmony with anxiety) and Tong Xie Yao Fang (painful diarrhea pattern)
  • Ayurvedic approaches: Vata‑pacifying diet, regular routine, triphala for bowel regulation, and ashwagandha or brahmi for anxiety
  • Yoga (gentle asana), pranayama (e.g., nadi shodhana), and meditation
Evidence: Emerging Research

Sources

  • Manheimer E et al. Cochrane Database Syst Rev. 2012;CD005111
  • Liu L et al. Neurogastroenterol Motil. 2015;27:1147-1157
  • Cramer H et al. Clin Gastroenterol Hepatol. 2015;13:1698-1709
  • Pratte MA et al. J Altern Complement Med. 2014;20:901-908

Evidence Ratings

Anxiety is significantly more prevalent in IBS than in the general population.

Zamani M et al. Aliment Pharmacol Ther. 2019;50:132-143.

Strong Evidence

Psychological therapies (CBT, hypnotherapy) improve global IBS symptoms and reduce anxiety.

Black CJ et al. Gut. 2020;69:1441-1451.

Strong Evidence

Low-dose TCAs reduce IBS pain and diarrhea; SSRIs/SNRIs help global symptoms and comorbid anxiety.

Ford AC et al. Am J Gastroenterol. 2019;114:1886-1900.

Moderate Evidence

Low-FODMAP diet reduces IBS symptoms; indirect improvements in anxiety occur via symptom relief.

Dionne J et al. Neurogastroenterol Motil. 2018;30:e13154.

Strong Evidence

Gut microbiota influence brain function and stress responses relevant to IBS and anxiety.

Cryan JF et al. Physiol Rev. 2019;99:1877-2013.

Moderate Evidence

Probiotics can modestly reduce anxiety in some populations; effects are strain-specific and inconsistent.

Ng QX et al. J Affect Disord. 2018;228:13-19.

Emerging Research

Acupuncture may improve IBS symptoms and anxiety via autonomic modulation, but evidence quality is mixed.

Manheimer E et al. Cochrane Database Syst Rev. 2012;CD005111.

Emerging Research

Western Medicine Perspective

From a Western viewpoint, IBS–anxiety comorbidity is a prototypical disorder of gut–brain interaction. Stress and anxiety heighten central sensitivity to visceral inputs, while peripheral changes in the gut—altered serotonin signaling, mast cell–neural crosstalk, bile acids, and microbial metabolites—amplify bottom‑up pain and dysmotility. These loops are maintained by attentional bias to gut sensations, fear‑avoidance behaviors (e.g., food or activity restriction), and poor sleep. Treatment therefore targets multiple nodes: cognitive behavioral therapy breaks catastrophic appraisals and safety behaviors; gut‑directed hypnotherapy normalizes autonomic tone and interoception; diet therapy (notably low‑FODMAP with careful reintroduction) reduces luminal triggers; regular exercise and sleep optimization downshift arousal. When medication is appropriate, low‑dose TCAs attenuate pain and slow diarrhea, while SSRIs/SNRIs treat anxiety and may aid global IBS symptoms—chosen thoughtfully by bowel pattern and side‑effect profile. Probiotics and mind–body practices offer adjunctive benefit for some, though effects are generally modest. The net principle is integrated care: screen for anxiety in IBS clinics, personalize a combined behavioral–dietary plan, and reserve pharmacotherapy strategically. This approach improves symptom burden, resilience, and quality of life more reliably than any single modality.

Eastern Medicine Perspective

Eastern traditions converge on a unifying picture: emotional constraint and erratic routines disturb digestive harmony and mental calm. TCM attributes stress‑reactive bowels and anxiety to Liver Qi stagnation disrupting Spleen/Stomach, with resultant Shen unrest; acupuncture harmonizes these systems and calms the mind, while formulas like Xiao Yao San or Tong Xie Yao Fang move Qi, relieve pain, and stabilize stools. Ayurveda similarly locates many IBS patterns in Vata aggravation and impaired Agni, manifesting as variable appetite, bloating, and anxious restlessness. Treatment emphasizes predictability—warm, easily digested foods; regular meals and sleep; gentle asana and pranayama to steady the nervous system—and selected herbs (e.g., ashwagandha for anxiety, triphala for bowel regularity) tailored to the individual constitution. Modern studies suggest these practices influence autonomic balance and inflammatory signaling, paralleling Western gut–brain models. Evidence quality varies, so many clinicians use these modalities as adjuncts to established care, particularly when patients value holistic, lifestyle‑forward approaches. The shared therapeutic north star is regulation: restore rhythmicity in diet, movement, and rest; soothe the stress response; and align mind and gut through attentive, personalized practice.

Sources
  1. Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116:17-44. doi:10.14309/ajg.0000000000001036
  2. Zamani M, Alizadeh-Tabari S, Zamani V. Systematic review with meta-analysis: the prevalence of anxiety and depression in irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50(2):132-143. doi:10.1111/apt.15223
  3. Black CJ, Thakur ER, Houghton LA, Quigley EMM, Moayyedi P, Ford AC. Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2020;69(8):1441-1451. doi:10.1136/gutjnl-2019-320041
  4. Ford AC, Lacy BE, Talley NJ. Antidepressants for irritable bowel syndrome and functional dyspepsia: systematic review and meta-analysis. Am J Gastroenterol. 2019;114(12):1886-1900. doi:10.14309/ajg.0000000000000420
  5. Dionne J, Ford AC, Yuan Y, et al. Efficacy of a low FODMAP diet for IBS: systematic review and meta-analysis. Neurogastroenterol Motil. 2018;30(2):e13154. doi:10.1111/nmo.13154
  6. Staudacher HM, Whelan K. The low FODMAP diet in the management of IBS. Nutrients. 2017;9(9):936. doi:10.3390/nu9090936
  7. Peters SL, Yao CK, Philpott H, et al. Randomised clinical trial: hypnotherapy vs low-FODMAP diet for IBS. Aliment Pharmacol Ther. 2016;44(5):447-459. doi:10.1111/apt.13706
  8. Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin Invest. 2015;125(3):926-938. doi:10.1172/JCI76304
  9. Cryan JF, O’Riordan KJ, Cowan CSM, et al. The Microbiota–Gut–Brain Axis. Physiol Rev. 2019;99(4):1877-2013. doi:10.1152/physrev.00018.2018
  10. Ng QX, Peters C, Ho CYX, Lim DY, Yeo WS. A meta-analysis of probiotics for anxiety and depression. J Affect Disord. 2018;228:13-19. doi:10.1016/j.jad.2017.11.063
  11. Labus JS, Hollister EB, Jacobs J, et al. Microbiome–brain correlations in IBS. Microbiome. 2017;5:49. doi:10.1186/s40168-017-0272-0
  12. Barbara G, Stanghellini V, De Giorgio R, et al. Mast cell infiltration in IBS. Gut. 2004;53:1492-1498. doi:10.1136/gut.2003.035451
  13. Cramer H, Klose P, et al. Yoga for IBS: systematic review. Clin Gastroenterol Hepatol. 2015;13(9):1698-1709. doi:10.1016/j.cgh.2015.02.023
  14. Manheimer E, Cheng K, Wieland LS, et al. Acupuncture for IBS. Cochrane Database Syst Rev. 2012;(5):CD005111. doi:10.1002/14651858.CD005111.pub3
  15. Pratte MA, Nanavati KB, Young V, Morley CP. Ashwagandha for anxiety: meta-analysis. J Altern Complement Med. 2014;20(12):901-908. doi:10.1089/acm.2014.0177
  16. Everitt HA, Landau S, O’Reilly G, et al. ACTIB trial—CBT for IBS in primary care. Gut. 2019;68:1613-1623. doi:10.1136/gutjnl-2018-317805

Related Topics

Health Disclaimer

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication regimen.